vmireavizВестник медицинского института «РЕАВИЗ». Реабилитация, Врач и ЗдоровьеBulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)2226-762X2782-1579РЕАВИЗ10.20340/vmi-rvz.2021.4.COVID.2vmireaviz-278Research ArticleНовая коронавирусная инфекция COVID-19Novel coronavirus infection COVID-19Вопросы вакцинации против COVID-19 у реципиентов трансплантатов солидных органовCOVID-19 Vaccination Issues in Solid Organ Transplant Recipientshttps://orcid.org/0000-0003-4520-8705ПарабинаЕ. В.ParabinaE. V.

Парабина Елена Валерьевна, заведующая нефрологическим отделением клиники факультетской терапии; руководитель центра по оказанию амбулаторно-поликлинической медицинской помощи и рациональному назначению лекарственных средств после трансплантации органов и(или) тканей МЗ Самарской области

Самара

Samara

https://orcid.org/0000-0002-6177-8487КонстантиновД. Ю.KonstantinovD. Yu.

Константинов Дмитрий Юрьевич, доктор медицинских наук, доцент, директор института клинической медицины, заведующий кафедрой инфекционных болезней с эпидемиологией

Самара

Samara

https://orcid.org/0000-0001-7566-2330КаабакМ. М.KaabakM. M.

Каабак Михаил Михайлович, доктор медицинских наук, профессор

Самара

Samara

https://orcid.org/0000-0002-4651-4061РаппопортН. Н.RappoportN. N.

Раппопорт Надежда Николаевна, врач-хирург

Самара

Samara

https://orcid.org/0000-0003-2206-6679ПушкинС. Ю.PushkinS. Yu.

Пушкин Сергей Юрьевич, доктор медицинских наук, доцент, профессор кафедры хирургических болезней № 2

Самара

Samara

https://orcid.org/0000-0002-3949-949XСелютинА. А.SelyutinA. A.

Селютин Александр Александрович, заведующий отделением по пересадке почки, врач-хирург

Оренбург

Orenburg

https://orcid.org/0000-0003-2007-6718НавасардянА. С.NavasardyanA. S.

Навасардян Альберт Степанович, заведующий отделением диализа № 1

Самара

Samara

https://orcid.org/0000-0002-3009-4744МасликоваУ. В.MaslikovaU. V.

Масликова Ульяна Владиславовна, врач-гематолог, аспирант

Москва

Moscow

https://orcid.org/0000-0002-5060-7041АлександроваВ. Э.AlexandrovaV. E.

Александрова Виктория Эдуардовна, младший научный сотрудник отделения анестезиологии

Москва

Moscow

https://orcid.org/0000-0001-5889-8675ЯреминБ. И.YareminB. I.

Яремин Борис Иванович, кандидат медицинских наук, доцент, главный специалист отдела внешних научных связей, врач-хирург центра трансплантации печени

Москва

Moscow

Самарский государственный медицинский университетРоссияSamara State Medical UniversityRussian FederationМедицинский университет «Реавиз»РоссияMedical University "Reaviz"Russian FederationСамарский государственный медицинский университет; Самарская областная клиническая больница им. В.Д. СередавинаРоссияSamara State Medical University; Samara Regional Clinical Hospital named. V.D. SeredavinaRussian FederationГородская клиническая больница № 1 города ОренбургаРоссияCity Clinical Hospital No. 1 of the city of OrenburgRussian FederationСамарская областная клиническая больница им. В.Д. СередавинаРоссияSamara Regional Clinical Hospital named. V.D. SeredavinaRussian FederationНациональный медицинский исследовательский центр гематологииРоссияNational Medical Research Center for HematologyRussian FederationНаучно-исследовательский институт скорой помощи им. Н.В. СклифосовскогоРоссияScientific Research Institute of Emergency Medicine named after N.V. SklifosovskyRussian Federation20212707202104514Copyright © Парабина Е.В., Константинов Д.Ю., Каабак М.М., Раппопорт Н.Н., Пушкин С.Ю., Селютин А.А., Навасардян А.С., Масликова У.В., Александрова В.Э., Яремин Б.И., 20212021Парабина Е.В., Константинов Д.Ю., Каабак М.М., Раппопорт Н.Н., Пушкин С.Ю., Селютин А.А., Навасардян А.С., Масликова У.В., Александрова В.Э., Яремин Б.И.Parabina E.V., Konstantinov D.Y., Kaabak M.M., Rappoport N.N., Pushkin S.Y., Selyutin A.A., Navasardyan A.S., Maslikova U.V., Alexandrova V.E., Yaremin B.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestnik.reaviz.ru/jour/article/view/278

Цель работы – дать основные ответы на вопросы, посвященные вакцинации реципиентов трансплантатов солидных органов на основе последних источников литературы и клинических рекомендаций. Вакцинация реципиентов трансплантатов солидных органов и лиц, находящихся с ними в постоянном контакте, является обязательным, жизненно важным мероприятием, эффективно снижающим риск смерти от COVID-19. Сомнения в меньшей эффективности в условиях иммуносупрессии или потенциальный риск развития нежелательных реакций значительно уступают риску смерти и развития тяжёлых осложнений. До появления более новых данных режим вакцинации должен строго соответствовать инструкции по медицинскому применению препарата. Перед трансплантацией пациент должен быть обследован по скрининговому протоколу, а также консультирован врачом-трансплантологом, осуществляющим его наблюдение. Возможно, что цельновирионные вакцины (КовиВак) имеют преимущество перед прочими при вакцинации реципиентов солидных органов, но клинический опыт в этом вопросе ещё не получен.

The aim of this work is to provide basic answers to questions related to the vaccination of solid organ transplant recipients based on the latest literature sources and clinical guidelines. Vaccination of solid organ transplants and persons in constant contact with them is a mandatory measure, the provision of which is a vital measure that effectively reduces the risk of death from COVID-19. Doubts about less effectiveness in conditions of immunosuppression or the potential risk of developing adverse reactions are significantly inferior to the risk of death and the development of severe complications. Until new data become available, the vaccination regimen must strictly comply with the instructions for medical use of the drug. Before transplantation, the patient should be examined according to the screening protocol, and also consulted by the transplant doctor who supervises him. It is possible that whole virion vaccines (CoviVac) have an advantage over others when vaccinating solid organ recipients, but clinical experience in this matter has not yet been obtained.

COVID-19вакцинацияСпутник-VКовиВакреципиенты солидных органовCOVID-19vaccinationSputnik-VKoviWaksolid organ recipientsРабота выполнена при спонсорской поддержке Научно-исследовательского центра инновационных решений в медицине, г. МоскваThe work was carried out with the sponsorship of the Research Center for Innovative Solutions in Medicine, MoscowReferencesBoyarsky BJ, Werbel WA, Avery RA, Tobian AAR, Massie AB, Segev DL, Garonzik-Wang JM: Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. JAMA. 2021.1 Boyarsky BJ, Werbel WA, Avery RA, Tobian AAR, Massie AB, Segev DL, Garonzik-Wang JM: Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. JAMA. 2021.Benotmane I, Gautier-Vargas G, Cognard N, Olagne J, Heibel F, Braun-Parvez L et al. Weak anti-SARSCoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients. Kidney Int. 2021.2 Benotmane I, Gautier-Vargas G, Cognard N, Olagne J, Heibel F, Braun-Parvez L et al. Weak anti-SARSCoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients. Kidney Int. 2021.Sattler A SE, Weber U, Potekhin A, Bachmann F, Budde K, Storz E, Proß V, Bergmann Y, Thole L, Tizian C, Hölsken O, Diefenbach A, Schrezenmeier H, Jahrsdörfer B, Zemojtel T, Jechow K, Conrad C, Lukassen S, Stauch D, Lachmann N, Choi M, Halleck F, Kotsch K. MedRxv. https://doi.org/10.1101/2021.04.06.21254963. Accessed 4/19/2021.3 Sattler A SE, Weber U, Potekhin A, Bachmann F, Budde K, Storz E, Proß V, Bergmann Y, Thole L, Tizian C, Hölsken O, Diefenbach A, Schrezenmeier H, Jahrsdörfer B, Zemojtel T, Jechow K, Conrad C, Lukassen S, Stauch D, Lachmann N, Choi M, Halleck F, Kotsch K. MedRxv. https://doi.org/10.1101/2021.04.06.21254963. Accessed 4/19/2021.Impaired Humoral and Cellular Immunity after SARS-CoV2 BNT162b2 (Tozinameran) Prime-Boost Vaccination in Kidney Transplant Recipients. Available from: Yi SG, Knight RJ, Graviss EA, Nguyen DT, Ghobrial RM, Gaber AO et al. Kidney Transplant Recipients Rarely Show an Early Antibody Response Following the First COVID-19 Vaccine Administration. Transplantation. 2021.4 Impaired Humoral and Cellular Immunity after SARS-CoV2 BNT162b2 (Tozinameran) Prime-Boost Vaccination in Kidney Transplant Recipients. Available from: Yi SG, Knight RJ, Graviss EA, Nguyen DT, Ghobrial RM, Gaber AO et al. Kidney Transplant Recipients Rarely Show an Early Antibody Response Following the First COVID-19 Vaccine Administration. Transplantation. 2021.Peled Y RE, Lavee J, Sternik L, Segev A, Wieder-Finesod A, Mandelboim M, Indenbaum V, Levy I, Raanani E, Lustig Y, Rahav G. BNT162b2 vaccination in heart transplant recipients: clinical experience and antibody response. J Heart Lung Transplant. 2021.5 Peled Y RE, Lavee J, Sternik L, Segev A, Wieder-Finesod A, Mandelboim M, Indenbaum V, Levy I, Raanani E, Lustig Y, Rahav G. BNT162b2 vaccination in heart transplant recipients: clinical experience and antibody response. J Heart Lung Transplant. 2021.Havlin J SM, Dvorackova E et al. Immunogenicity of BNT162b2 mRNA COVID19 Vaccine and SARS-CoV-2 Infection in Lung Transplant Recipients. Journal of Heart and Lung Transplantation. 2021.6 Havlin J SM, Dvorackova E et al. Immunogenicity of BNT162b2 mRNA COVID19 Vaccine and SARS-CoV-2 Infection in Lung Transplant Recipients. Journal of Heart and Lung Transplantation. 2021.Narasimhan M ML, Clark AE, Usmani A, Cao J, Raj E, Torres F, Sarode R, Kaza V, Lacelle C, Muthukumar A. Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines. medRxiv 2021.7 Narasimhan M ML, Clark AE, Usmani A, Cao J, Raj E, Torres F, Sarode R, Kaza V, Lacelle C, Muthukumar A. Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines. medRxiv 2021.Shostak Y SN, Heching M, Rosengarten D, Shtraichman O, Shitenberg D, Amor SM, Yahav D, Zvi HB, Pertzov B, Kramer MR. Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine. The Lancet Resp Med. 2021. v. 5 07.13.20218 Shostak Y SN, Heching M, Rosengarten D, Shtraichman O, Shitenberg D, Amor SM, Yahav D, Zvi HB, Pertzov B, Kramer MR. Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine. The Lancet Resp Med. 2021. v. 5 07.13.2021Miele M, Busa R, Russelli G, Sorrentino MC, Di Bella M, Timoneri F et al. Impaired anti-SARS-CoV-2 Humoral and Cellular Immune Response induced by Pfizer-BioNTech BNT162b2 mRNA Vaccine in Solid Organ Transplanted Patients. Am J Transplant. 2021.9 Miele M, Busa R, Russelli G, Sorrentino MC, Di Bella M, Timoneri F et al. Impaired anti-SARS-CoV-2 Humoral and Cellular Immune Response induced by Pfizer-BioNTech BNT162b2 mRNA Vaccine in Solid Organ Transplanted Patients. Am J Transplant. 2021.Cucchiari D, Egri N, Bodro M, Herrera S, Del Risco-Zevallos J, Casals-Urquiza J et al. Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. Am J Transplant. 2021.10 Cucchiari D, Egri N, Bodro M, Herrera S, Del Risco-Zevallos J, Casals-Urquiza J et al. Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. Am J Transplant. 2021.Rozen-Zvi B, Yahav D, Agur T, Zingerman B, Ben-Zvi H, Atamna A et al. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study. Clin Microbiol Infect. 2021.11 Rozen-Zvi B, Yahav D, Agur T, Zingerman B, Ben-Zvi H, Atamna A et al. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study. Clin Microbiol Infect. 2021.Rabinowich L, Grupper A, Baruch R, Ben-Yehoyada M, Halperin T, Turner D et al. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. J Hepatol. 2021.12 Rabinowich L, Grupper A, Baruch R, Ben-Yehoyada M, Halperin T, Turner D et al. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. J Hepatol. 2021.Grupper A, Rabinowich L, Schwartz D, Schwartz IF, Ben-Yehoyada M, Shashar M et al. Reduced humoral response to mRNA SARS-Cov-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant. 2021.13 Grupper A, Rabinowich L, Schwartz D, Schwartz IF, Ben-Yehoyada M, Shashar M et al. Reduced humoral response to mRNA SARS-Cov-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant. 2021.Itzhaki Ben Zadok O, Shaul AA, Ben-Avraham B, Yaari V, Ben Zvi H, Shostak Y et al. Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients – a prospective cohort study. Eur J Heart Fail. 2021CHC Inc. (n.d.).14 Itzhaki Ben Zadok O, Shaul AA, Ben-Avraham B, Yaari V, Ben Zvi H, Shostak Y et al. Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients – a prospective cohort study. Eur J Heart Fail. 2021CHC Inc. (n.d.).Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021). Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine. https://doi.org/10.1038/s41591-021-01377-815 Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021). Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine. https://doi.org/10.1038/s41591-021-01377-8Basic-Jukic N, Jelicic I. SARS-CoV-2 infection after two doses of mRNA vaccine in renal transplant recipients. Transpl Infect Dis. 2021:e13628.16 Basic-Jukic N, Jelicic I. SARS-CoV-2 infection after two doses of mRNA vaccine in renal transplant recipients. Transpl Infect Dis. 2021:e13628.Tsalouchos A, Rossolini GM, Magg L, Mazzoni A, Annunziato F, Dattolo PC. COVID-19 in a kidney transplant recipient after mRNA-based SARS-CoV-2 vaccination. Transpl Infect Dis. 2021:e13649.17 Tsalouchos A, Rossolini GM, Magg L, Mazzoni A, Annunziato F, Dattolo PC. COVID-19 in a kidney transplant recipient after mRNA-based SARS-CoV-2 vaccination. Transpl Infect Dis. 2021:e13649.Tau N, Yahav D, Schneider S, Rozen-Zvi B, Abu Sneineh M, Rahamimov R. Severe consequences of COVID-19 infection among vaccinated kidney transplant recipients. Am J Transplant. 2021.18 Tau N, Yahav D, Schneider S, Rozen-Zvi B, Abu Sneineh M, Rahamimov R. Severe consequences of COVID-19 infection among vaccinated kidney transplant recipients. Am J Transplant. 2021.CDC Director Rochelle Walensky Talks Boosters, Masks and Health Equity. Home – Community Health Center Presents Conversations on Health Care. https://www.chcradio.com/episode/Rochelle-Walensky/579.19 CDC Director Rochelle Walensky Talks Boosters, Masks and Health Equity. Home – Community Health Center Presents Conversations on Health Care. https://www.chcradio.com/episode/Rochelle-Walensky/579.U.S. Department of Health and Human Services. (2021, June 1). NIH clinical trial evaluating mixed COVID-19 vaccine schedules begins. National Institutes of Health. https://www.nih.gov/news-e vents/newsreleases/nih-clinical-trial-evaluating-mixed-covid-19-vaccine-schedules-begins20 U.S. Department of Health and Human Services. (2021, June 1). NIH clinical trial evaluating mixed COVID-19 vaccine schedules begins. National Institutes of Health. https://www.nih.gov/news-e vents/newsreleases/nih-clinical-trial-evaluating-mixed-covid-19-vaccine-schedules-beginsKamar, N., Abravanel, F., Marion, O., Couat, C., Izopet, J., & Del Bello, A. (2021). Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. New England Journal of Medicine. https://doi.org/10.1056/nejmc210886121 Kamar, N., Abravanel, F., Marion, O., Couat, C., Izopet, J., & Del Bello, A. (2021). Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. New England Journal of Medicine. https://doi.org/10.1056/nejmc2108861Werbel, W. A., Boyarsky, B. J., Ou, M. T., Massie, A. B., Tobian, A. A. R., Garonzik-Wang, J. M., & Segev, D. L. (2021). Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Annals of Internal Medicine. https://doi.org/10.7326/l21-028222 Werbel, W. A., Boyarsky, B. J., Ou, M. T., Massie, A. B., Tobian, A. A. R., Garonzik-Wang, J. M., & Segev, D. L. (2021). Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Annals of Internal Medicine. https://doi.org/10.7326/l21-0282Joint Statement about Vaccine Efficacy in Organ Transplant Recipients. AST. ISHLT. ASTS. TTS. TID. IPTA. ISVCA. IRT. IXA. ISODT. SPLIT. IPITA. NATCO. UNOS. CST. ESOT. AASLD. ASHI. ITNS. AOPO. PIDS. https://ishlt.org/ishlt/media/documents/ISHLT-AST_SARS-CoV-2-Vaccination_7-15-21.pdf23 Joint Statement about Vaccine Efficacy in Organ Transplant Recipients. AST. ISHLT. ASTS. TTS. TID. IPTA. ISVCA. IRT. IXA. ISODT. SPLIT. IPITA. NATCO. UNOS. CST. ESOT. AASLD. ASHI. ITNS. AOPO. PIDS. https://ishlt.org/ishlt/media/documents/ISHLT-AST_SARS-CoV-2-Vaccination_7-15-21.pdfPolack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Moreira ED, Zerbini Cet al: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020.24 Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Moreira ED, Zerbini Cet al: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020.Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QEet al: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020.25 Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QEet al: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020.Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CBet al: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020.26 Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CBet al: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020.Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova ASet al: Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021,397(10275):671-681.27 Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova ASet al: Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021,397(10275):671-681.Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial. Accessed 3/13/2021 [https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3]28 Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial. Accessed 3/13/2021 [https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3]Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernan MA, Lipsitch M, Reis B, Balicer RD: BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021. 30 Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, Bedston S, Beggs J, Bradley D, Chuter Aet al: Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021;397(10285):1646-1657.29 Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernan MA, Lipsitch M, Reis B, Balicer RD: BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021. 30 Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, Bedston S, Beggs J, Bradley D, Chuter Aet al: Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021;397(10285):1646-1657.Pritchard E MP, Stoesser N, Eyre DW, Gethings O, Vihta K, Jones J, House T, VanSteenHouse H, Bell I Bell JI, Newton JN, Farrar J, Diamond A, Rourke E, Studley R, Crook D, Peto T, Walker AS, Pouwels KB, Coronavirus Infection Survey team: Impact of vaccination on SARS-CoV-2 cases in the community: a populationbased study using the UK’s COVID-19 Infection Survey. medRxiv Posted April 23, 2021.31 Pritchard E MP, Stoesser N, Eyre DW, Gethings O, Vihta K, Jones J, House T, VanSteenHouse H, Bell I Bell JI, Newton JN, Farrar J, Diamond A, Rourke E, Studley R, Crook D, Peto T, Walker AS, Pouwels KB, Coronavirus Infection Survey team: Impact of vaccination on SARS-CoV-2 cases in the community: a populationbased study using the UK’s COVID-19 Infection Survey. medRxiv Posted April 23, 2021.NYT Vaccinations Tracker. Accessed 3/13/21 [https://www.nytimes.com/interactive/2021/world/covidvaccinations-tracker.html]32 NYT Vaccinations Tracker. Accessed 3/13/21 [https://www.nytimes.com/interactive/2021/world/covidvaccinations-tracker.html]Shimabukuro TT, Cole M, Su JR: Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021. JAMA. 2021.33 Shimabukuro TT, Cole M, Su JR: Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021. JAMA. 2021.Blumenthal KG, Robinson LB, Camargo CA, Jr., Shenoy ES, Banerji A, Landman AB, Wickner P: Acute Allergic Reactions to mRNA COVID-19 Vaccines. JAMA. 2021.34 Blumenthal KG, Robinson LB, Camargo CA, Jr., Shenoy ES, Banerji A, Landman AB, Wickner P: Acute Allergic Reactions to mRNA COVID-19 Vaccines. JAMA. 2021.Chan BT BP, Odutayo A, Pai M: Meta-Analysis of Risk of Vaccine-Induced Immune Thrombotic Thrombocytopenia Following ChAdOx1-S Recombinant Vaccine.medRxiv Posted May 8, 2021 2021.35 Chan BT BP, Odutayo A, Pai M: Meta-Analysis of Risk of Vaccine-Induced Immune Thrombotic Thrombocytopenia Following ChAdOx1-S Recombinant Vaccine.medRxiv Posted May 8, 2021 2021.Schultz NH, Sorvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, Wiedmann M, Aamodt AH, Skattor TH, Tjonnfjord GEet al: Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021.36 Schultz NH, Sorvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, Wiedmann M, Aamodt AH, Skattor TH, Tjonnfjord GEet al: Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021.Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S: Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med. 2021.37 Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S: Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med. 2021.Shay DK, Gee J, Su JR, Myers TR, Marquez P, Liu R, Zhang B, Licata C, Clark TA, Shimabukuro TT: Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine -United States, March-April 2021. MMWR Morb Mortal Wkly Rep. 2021;70(18):680-684.38 Shay DK, Gee J, Su JR, Myers TR, Marquez P, Liu R, Zhang B, Licata C, Clark TA, Shimabukuro TT: Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine -United States, March-April 2021. MMWR Morb Mortal Wkly Rep. 2021;70(18):680-684.Brian J. Boyarsky WAW, Robin K. Avery, Aaron A. R. Tobian, Allan B. Massie, Dorry L. Segev, Jacqueline M. Garonzik-Wang: Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. JAMA. 2021.39 Brian J. Boyarsky WAW, Robin K. Avery, Aaron A. R. Tobian, Allan B. Massie, Dorry L. Segev, Jacqueline M. Garonzik-Wang: Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. JAMA. 2021.Grupper A, Rabinowich L, Schwartz D, Schwartz IF, Ben-Yehoyada M, Shashar M, Katchman E, Halperin T, Turner D, Goykhman Yet al: Reduced humoral response to mRNA SARS-Cov-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant. 2021.40 Grupper A, Rabinowich L, Schwartz D, Schwartz IF, Ben-Yehoyada M, Shashar M, Katchman E, Halperin T, Turner D, Goykhman Yet al: Reduced humoral response to mRNA SARS-Cov-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant. 2021.Impaired Humoral and Cellular Immunity after SARS-CoV2 BNT162b2 (Tozinameran) Prime-Boost Vaccination in Kidney Transplant Recipients.41 Impaired Humoral and Cellular Immunity after SARS-CoV2 BNT162b2 (Tozinameran) Prime-Boost Vaccination in Kidney Transplant Recipients.Peled Y RE, Lavee J, Sternik L, Segev A, Wieder-Finesod A, Mandelboim M, Indenbaum V, Levy I, Raanani E, Lustig Y, Rahav G: BNT162b2 vaccination in heart transplant recipients: clinical experience and antibodyresponse. J Heart Lung Transplant. 2021.42 Peled Y RE, Lavee J, Sternik L, Segev A, Wieder-Finesod A, Mandelboim M, Indenbaum V, Levy I, Raanani E, Lustig Y, Rahav G: BNT162b2 vaccination in heart transplant recipients: clinical experience and antibodyresponse. J Heart Lung Transplant. 2021.Havlin J SM, Dvorackova E et al. : Immunogenicity of BNT162b2 mRNA COVID19 Vaccine and SARS-CoV-2 Infection in LungTransplant Recipients. Journal of Heart and Lung Transplantation. 2021.43 Havlin J SM, Dvorackova E et al. : Immunogenicity of BNT162b2 mRNA COVID19 Vaccine and SARS-CoV-2 Infection in LungTransplant Recipients. Journal of Heart and Lung Transplantation. 2021.Boyarsky BJ, Ou MT, Greenberg RS, Teles AT, Werbel WA, Avery RK, Massie AB, Segev DL, Garonzik- Wang JM: Safety of the First Dose of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients. Transplantation. 2021.44 Boyarsky BJ, Ou MT, Greenberg RS, Teles AT, Werbel WA, Avery RK, Massie AB, Segev DL, Garonzik- Wang JM: Safety of the First Dose of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients. Transplantation. 2021.Vink P, Ramon Torrell JM, Sanchez Fructuoso A, Kim SJ, Kim SI, Zaltzman J, Ortiz F, Campistol Plana JM, Fernandez Rodriguez AM, Rebollo Rodrigo Het al: Immunogenicity and Safety of the Adjuvanted Recombinant ZosterVaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial. Clin Infect Dis. 2020;70(2):181-190.45 Vink P, Ramon Torrell JM, Sanchez Fructuoso A, Kim SJ, Kim SI, Zaltzman J, Ortiz F, Campistol Plana JM, Fernandez Rodriguez AM, Rebollo Rodrigo Het al: Immunogenicity and Safety of the Adjuvanted Recombinant ZosterVaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial. Clin Infect Dis. 2020;70(2):181-190.Natori Y, Shiotsuka M, Slomovic J, Hoschler K, Ferreira V, Ashton P, Rotstein C, Lilly L, Schiff J, Singer Let al: A Double-Blind, Randomized Trial of High-Dose vs Standard-Dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients. Clin Infect Dis. 2018;66(11):1698-1704.46 Natori Y, Shiotsuka M, Slomovic J, Hoschler K, Ferreira V, Ashton P, Rotstein C, Lilly L, Schiff J, Singer Let al: A Double-Blind, Randomized Trial of High-Dose vs Standard-Dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients. Clin Infect Dis. 2018;66(11):1698-1704.Sette A, Crotty S: Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861-880. 48 SARS-CoV-2 Vaccination in Heart and Lung Transplantation, MCS and PHRecommendations from the ISHLT COVID-19 Task Force. May 21, 2021. https://ishlt.org/ishlt/media/documents/COVID19_Vaccine-Recommendations_5-21-2021.pdf47 Sette A, Crotty S: Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861-880. 48 SARS-CoV-2 Vaccination in Heart and Lung Transplantation, MCS and PHRecommendations from the ISHLT COVID-19 Task Force. May 21, 2021. https://ishlt.org/ishlt/media/documents/COVID19_Vaccine-Recommendations_5-21-2021.pdfCOVID-19 Treatment Guidelines34017.Montagud-Marrahi E, Cofan F, Torregrosa JV, et al. Preliminary data on outcomes of SARS-CoV-2 infection in a Spanish single center cohort of kidney recipients. Am J Transplant. 2020;20(10):2958-2959. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32368838.49 COVID-19 Treatment Guidelines34017.Montagud-Marrahi E, Cofan F, Torregrosa JV, et al. Preliminary data on outcomes of SARS-CoV-2 infection in a Spanish single center cohort of kidney recipients. Am J Transplant. 2020;20(10):2958-2959. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32368838.Kates OS, Haydel BM, Florman SS, et al. COVID-19 in solid organ transplant: a multi-center cohort study. Clin Infect Dis. 2020. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32766815.50 Kates OS, Haydel BM, Florman SS, et al. COVID-19 in solid organ transplant: a multi-center cohort study. Clin Infect Dis. 2020. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32766815.Sharma A, Bhatt NS, St. Martin A, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021;8(3):e185-e193. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33482113.51 Sharma A, Bhatt NS, St. Martin A, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021;8(3):e185-e193. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33482113.Shah GL, DeWolf S, Lee YJ, et al. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Invest. 2020;130(12):6656-6667. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32897885.52 Shah GL, DeWolf S, Lee YJ, et al. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Invest. 2020;130(12):6656-6667. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32897885.Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020;383(26):2586-2588. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33259154.53 Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020;383(26):2586-2588. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33259154.Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384(8):693-704. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32678530.54 Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384(8):693-704. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32678530.Horby PW, Pessoa-Amorim G, Peto L, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv. 2021;preprint. Available at: https://www.medrxiv.org/content/10.1101/2021.02.11.21249258v1.55 Horby PW, Pessoa-Amorim G, Peto L, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv. 2021;preprint. Available at: https://www.medrxiv.org/content/10.1101/2021.02.11.21249258v1.Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N Engl J Med. 2021. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33631065.56 Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N Engl J Med. 2021. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33631065.American Association for the Study of Liver Diseases. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. 2021. Available at: https://www.aasld.org/sites/default/files/2021-03/AASLD-COVID19-ExpertPanelConsensusStatement-March92021.pdf. Accessed April 12, 2021.57 American Association for the Study of Liver Diseases. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. 2021. Available at: https://www.aasld.org/sites/default/files/2021-03/AASLD-COVID19-ExpertPanelConsensusStatement-March92021.pdf. Accessed April 12, 2021.Elens L, Langman LJ, Hesselink DA, et al. Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions. Ther Drug Monit. 2020;42(3):360-368. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32304488.58 Elens L, Langman LJ, Hesselink DA, et al. Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions. Ther Drug Monit. 2020;42(3):360-368. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32304488.Special Considerations in Solid Organ Transplant, Hematopoietic Stem Cell Transplant, and Cellular Therapy Candidates, Donors, and Recipients. Section 84. COVID-19 and Special Populations. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed July 19th, 2021.59 Special Considerations in Solid Organ Transplant, Hematopoietic Stem Cell Transplant, and Cellular Therapy Candidates, Donors, and Recipients. Section 84. COVID-19 and Special Populations. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed July 19th, 2021.

The authors declare that there are no conflicts of interest present.